Close
Company Search
Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Glaxosmithkline (GSK) Share Price

Price 1,779.50p on 02-10-2026 at 17:35:10
Change -15.50p -0.86%
Buy 1,776.00p
Sell 1,775.50p
Add to Watchlist
Add to Portfolio
Add to Quickpicks
Last Trade: Sell 4,744.00 at 1,779.50p
Day's Volume: 5,629,788
Last Close: 1,779.50p
Open: 1,781.00p
ISIN: GB00BN7SWP63
Day's Range 1,770.00p - 1,802.00p
52wk Range: 1,592.00p - 2,282.00p
Market Capitalisation: £71.30b
VWAP: 1,780.76101p
Shares in Issue: 4.01b

Sector: Medicine and Biotech

Listed In: FTSE All-Share, FTSE All-Share ex Investment Trusts, FTSE Higher Yield, FTSE 350 ex Investment Trusts, FTSE 350 , FTSE 100,

Glaxosmithkline (GSK) Latest Trades

Buy/Sell Volume Trade Prc Trade Type Trade Time
Sell* 4,744 1,779.50p Automatic Execution
 16:37:22 - 02-Oct-26
Sell* 4,744 1,779.50p Automatic Execution
 16:37:20 - 02-Oct-26
Buy* 379 1,779.50p Automatic Execution
 16:37:20 - 02-Oct-26
Buy* 399 1,779.50p Automatic Execution
 16:36:18 - 02-Oct-26
Sell* 7,116 1,779.50p Automatic Execution
 16:36:15 - 02-Oct-26
Buy* 376 1,779.50p Automatic Execution
 16:36:15 - 02-Oct-26
Buy* 307 1,779.50p Automatic Execution
 16:36:15 - 02-Oct-26
Buy* 599 1,779.50p Automatic Execution
 16:36:15 - 02-Oct-26
Buy* 199 1,779.50p Automatic Execution
 16:36:15 - 02-Oct-26
Buy* 199 1,779.50p Automatic Execution
 16:36:15 - 02-Oct-26
See more Glaxosmithkline trades

Glaxosmithkline (GSK) Share Price History

Time period:
to
Date Open High Low Close Volume
2nd Oct 2026 (Fri) 1,781.00 1,802.00 1,770.00 1,779.50 5,629,788
1st Oct 2026 (Thu) 1,810.50 1,830.50 1,790.50 1,795.00 8,592,563
30th Sep 2026 (Wed) 1,864.50 1,873.50 1,824.50 1,832.00 9,778,649
29th Sep 2026 (Tue) 1,866.50 1,917.00 1,852.00 1,856.00 8,485,936
28th Sep 2026 (Mon) 1,863.00 1,872.00 1,841.00 1,860.00 4,381,276
25th Sep 2026 (Fri) 1,872.00 1,891.00 1,851.00 1,851.00 6,920,309
24th Sep 2026 (Thu) 1,873.00 1,896.00 1,863.00 1,877.00 3,578,575
23rd Sep 2026 (Wed) 1,895.50 1,912.50 1,874.50 1,886.00 6,310,501
22nd Sep 2026 (Tue) 1,913.50 1,913.50 1,881.00 1,906.00 5,135,262
21st Sep 2026 (Mon) 1,878.00 1,916.00 1,868.50 1,911.00 6,861,145
18th Sep 2026 (Fri) 1,907.00 1,912.00 1,852.50 1,877.50 15,668,260
17th Sep 2026 (Thu) 1,885.50 1,906.50 1,872.00 1,900.00 9,893,739
16th Sep 2026 (Wed) 1,855.50 1,883.50 1,853.50 1,865.50 7,165,366
15th Sep 2026 (Tue) 1,862.50 1,876.50 1,839.00 1,854.00 4,901,615
14th Sep 2026 (Mon) 1,800.00 1,870.00 1,789.50 1,854.50 4,365,126
11th Sep 2026 (Fri) 1,786.00 1,804.00 1,770.00 1,770.50 3,933,904
10th Sep 2026 (Thu) 1,800.00 1,803.50 1,775.50 1,775.50 3,018,164
9th Sep 2026 (Wed) 1,776.00 1,812.50 1,772.00 1,803.50 3,659,124
8th Sep 2026 (Tue) 1,824.00 1,829.50 1,782.00 1,796.50 5,349,814
7th Sep 2026 (Mon) 1,834.50 1,849.00 1,825.50 1,837.50 4,622,327
4th Sep 2026 (Fri) 1,866.00 1,869.00 1,835.50 1,846.50 3,782,286
3rd Sep 2026 (Thu) 1,871.00 1,911.00 1,858.50 1,866.50 4,089,291
See more Glaxosmithkline price history

Glaxosmithkline (GSK) Regulatory News

Date Source Headline
1st Oct 2026 3:00 pm RNS Total Voting Rights
24th Sep 2026 3:30 pm RNS Director/PDMR Shareholding
22nd Sep 2026 3:30 pm RNS Director/PDMR Shareholding
15th Sep 2026 7:00 am RNS GSK to acquire T cell-engager for multiple myeloma
14th Sep 2026 7:00 am RNS Ris-Rez Positive Ph 3 OS Lung Cancer Data in China
14th Sep 2026 7:00 am RNS Jideytro positive data for ROS1-positive NSCLC
11th Sep 2026 3:30 pm RNS Director/PDMR Shareholding
10th Sep 2026 3:30 pm RNS Director/PDMR Shareholding
10th Sep 2026 7:00 am RNS Japan approval of Shingrix in a prefilled syringe
9th Sep 2026 3:30 pm RNS Director/PDMR Shareholding
See more Glaxosmithkline regulatory news

Glaxosmithkline (GSK) Share News

UK dividends calendar - next 7 days

1st Oct 2026 12:05

Read More

LONDON MARKET MIDDAY: Stocks rise as oil prices edge down

29th Sep 2026 12:09

(Alliance News) - Stock prices in London were higher at midday on Tuesday, as pharmaceutical stocks advanced and investors digested UK mortgage data showing approvals at their lowest level since the end of 2023. Read More

WINNERS & LOSERS: Vesuvius soars on bid; Zigup lifts outlook

29th Sep 2026 10:21

(Alliance News) - The following are the leading risers and fallers among FTSE 100 and 250 index constituents on Tuesday. Read More

LONDON MARKET OPEN: Stocks rise as pharma and miners advance

29th Sep 2026 09:09

(Alliance News) - Stock prices in London opened higher on Tuesday, as pharmaceutical and mining stocks advanced, while oil prices eased amid signs of progress towards renewed talks between the US and Iran. Read More

IN BRIEF: Hutchmed begins phase Ia trial of HMPL-A830 in China

28th Sep 2026 11:10

Hutchmed China Ltd - Hong Kong-based biopharmaceutical company - Initiates the phase Ia portion, or initial dose-finding stage, of a global clinical trial of HMPL-A830 in patients with advanced or metastatic solid tumours. Says the first patient received an initial dose in China on September 24. The phase I study will assess safety, tolerability, pharmacokinetics, immunogenicity and preliminary efficacy, with the initial dose-escalation stage intended to determine the maximum tolerated dose and recommended dose for expansion. Hutchmed says the antibody-targeted therapy combines a KRAS inhibitor with an anti-EGFR antibody to target KRAS-altered, EGFR-expressing tumours. The company is responsible for global phase I development under an agreement with GSK, which holds worldwide rights outside mainland China, Hong Kong, Macau and Taiwan. Read More

See more Glaxosmithkline news
FTSE 100 Latest
Value10,461.95
Change33.68

Login to your account

Forgot Password?

Not Registered